학술논문
Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3b Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies
Document Type
Article
Author
Carneiro, B.A.; Safran, H.; Borden, B.A.; Cavalcante, L.; Mahalingam, D.; Saeed, A.; Ma, W.W.; Coveler, A.L.; Powell, S.; Bastos, B.; Davis, E.; Sahai, V.; Mikrut, W.; Longstreth, J.; Smith, S.; Weisskittel, T.; Li, H.; Harvey, R.D.; Sahebjam, S.; Cervantes, A.; Koukol, A.; Mazar, A.P.; Steeghs, N.; Kurzrock, R.; Giles, F.J.; Munster, P.
Source
In: Clinical Cancer Research . (Clinical Cancer Research, 1 February 2024, 30(3):522-531)
Subject
Language
English
ISSN
15573265
10780432
10780432